A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection - Full Text View

Study Description

Brief Summary:

To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT) when given in combination.

Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with AIDS, and probably with AIDS related complex (ARC), will be receiving AZT. Because AZT is reported not to be active against cytomegalovirus (CMV), it is important to see if it is useful to give GCV along with AZT.

Condition or disease	Intervention/treatment	Phase
Cytomegalovirus Infections HIV Infections	Drug: Zidovudine Drug: Ganciclovir	Not Applicable

Detailed Description:

Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with AIDS, and probably with AIDS related complex (ARC), will be receiving AZT. Because AZT is reported not to be active against cytomegalovirus (CMV), it is important to see if it is useful to give GCV along with AZT.

Patients are placed into one of four groups at entry into study according to their previous treatment:

I: Prior treatment with AZT up to the time of developing CMV infection and not requiring dose reduction of AZT for toxicity.

II: Prior treatment with AZT up to the time of developing CMV infection and requiring dose reduction of AZT for toxicity.

III: Prior therapy with GCV for CMV infection. These patients should already be in the maintenance phase, having completed a minimum of 2 weeks of induction therapy.

IV: No prior therapy with either AZT or GCV.

Treatment lasts 24 weeks and consists of two treatment plans:

A: Patients not previously treated with GCV are started on GCV for an additional 22 weeks. GCV is given as a 1-hour infusion. All patients are started on AZT at the lowest dose. B: For patients with chronic CMV disease who are receiving GCV maintenance, GCV is administered as a 1-hour infusion 5 days/week.

AZT is added and treatment with GCV is standardized prior to beginning of the study.

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	60 participants
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Phase I Studies of the Combination of AZT and DHPG (Ganciclovir) in Patients With AIDS and Cytomegalovirus Infection
Actual Study Completion Date :	February 1990

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cytomegalovirus Infections HIV/AIDS

Drug Information available for: Zidovudine Ganciclovir Ganciclovir sodium

Genetic and Rare Diseases Information Center resources: Cytomegalic Inclusion Disease

U.S. FDA Resources

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Symptomatic therapy such as analgesics, antihistamines, antiemetics, and antidiarrheal agents, or other supportive therapy may be administered as deemed necessary by the responsible investigator. For fever, the following regimens should be used:
If fever above 39.0 degrees C, antipyretic therapy will be administered employing aspirin, 650 mg orally every 4 hours x 3 doses, or until fever falls below 39.0 degrees C.
If fever of higher than 39.0 degrees C occurs for 2 consecutive days, the patient may be premedicated with aspirin.

Exclusion Criteria

Active alcohol or drug abuse.

Co-existing Condition:

Excluded:

Patients with other life-threatening and uncontrolled opportunistic infections on enrollment.

Patients with the following prior conditions are excluded if they:

Have other life-threatening and uncontrolled opportunistic infections on enrollment.

Prior Medication:

Excluded within 1 week of study entry:

Systemic therapy with antimetabolite.
Cytotoxic drug.
Interferon.
Immunologic modulators.
Corticosteroids.
Nucleoside analogs other than zidovudine (AZT).
Excluded within 2 weeks of study entry:
Therapy for any other opportunistic infections.
Excluded within 2 months of study entry:
Ribavirin.

Prior Treatment:

Excluded within 2 weeks of study entry (for treatment group I):

Blood transfusion.
Excluded within 1 month of study entry (for treatment groups II and III):
Blood transfusion.

All patients must be:

Able to provide informed consent.
Likely to be available for follow-up for at least 4 months.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000995

Locations


United States, California
Univ of California / San Diego Treatment Ctr
San Diego, California, United States, 921036325
United States, New York
Bellevue Hosp / New York Univ Med Ctr
New York, New York, United States, 10016
Univ of Rochester Medical Center
Rochester, New York, United States, 14642

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators


Study Chair:	Reichman RC
Study Chair:	Richman D
Study Chair:	Hochster H

More Information

Publications:

Hochster H, Dieterich D, Bozzette S, Reichman RC, Connor JD, Liebes L, Sonke RL, Spector SA, Valentine F, Pettinelli C, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med. 1990 Jul 15;113(2):111-7.


Responsible Party:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00000995 History of Changes
Other Study ID Numbers:	ACTG 004 10980 ( Registry Identifier: DAIDS ES Registry Number )
First Posted:	August 31, 2001 Key Record Dates
Last Update Posted:	February 17, 2012
Last Verified:	February 2012

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):


AIDS-Related Opportunistic Infections Ganciclovir Drug Evaluation Drug Therapy, Combination	Cytomegalovirus Infections Acquired Immunodeficiency Syndrome Zidovudine

Additional relevant MeSH terms:


Infection Communicable Diseases HIV Infections Cytomegalovirus Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Herpesviridae Infections	DNA Virus Infections Zidovudine Ganciclovir Ganciclovir triphosphate Antimetabolites Molecular Mechanisms of Pharmacological Action Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents